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Lung cancer remains one of the most common cancers, and the mortality rate 
is still high. Radiotherapy plays an important role in radical treatment for locally 
advanced non-small cell lung cancer. Treatment outcomes in lung cancer have 
improved over the last few decades. Several treatment regimens have been shown 
to be effective and safe. Further, modern technological approaches of radiotherapy 
have been developed along with advanced imaging and immunotherapy in order to 
improve outcomes and minimize radiation-induced toxicity. This chapter sum-
marizes the historical results of the key clinical studies that were conducted in the 
past with the focus on various regimens of chemoradiotherapy used. In addition, we 
discuss future perspectives of definitive radiotherapy for locally advanced non-
small cell lung cancer.
Keywords: lung cancer, radiotherapy, chemoradiotherapy, intensity modulated 
radiation therapy, dulvalumab
1. Introduction
The lung cancer remains one of the most common cancers, and 80% of lung 
cancers account for non-small cell lung cancer (NSCLC) [1]. Patients diagnosed 
at a locally advanced stage represent 20 to 30%, and radical surgery is challenging 
for those patients [1]. Definitive chemoradiotherapy is a well-established treat-
ment option for unresectable locally advanced NSCLC [2, 3]. Treatment outcomes 
in such patients have improved over the last few decades. Several treatment 
regimens have been shown to be effective and safe. Moreover, modern radio-
therapy technologies have been developed along with the development of optimal 
chemotherapy and immunotherapy to improve outcomes and minimize radiation-
induced toxicity. This chapter summarizes historical results of key clinical studies 
in the past in terms of various regimens of chemoradiotherapy. In addition, we 
discuss definitive radiotherapy, which is recommended for locally advanced 
NSCLC. Specifically, we address future perspectives of definitive radiotherapy for 
locally advanced NSCLC.
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2.  History of the development of definitive radiotherapy for locally 
advanced NSCLC
Radiotherapy alone was a standard treatment for inoperable lung cancer up 
to the 1980s based on the results of a randomized controlled trial in the 1960s 
[4]. Perez et al. showed the dose–response efficacy up to 60 Gy, which had been 
a standard dose from the combined results of the RTOG 7101 and 73–02 study 
[5]. After the 1990s, definitive radiotherapy, using ≥60Gy in a conventional 
fractionated regimen, combined with chemotherapy, has been used as a standard 
treatment for unresectable locally advanced NSCLC. In the early 1990s, sequential 
cisplatin-based chemotherapy followed by radiotherapy had been proven to 
have a survival benefit over definitive radiotherapy alone and chemotherapy 
alone for unresectable stage III NSCLC [6–9]. Then, from the late 1990s to the 
2000s, several randomized clinical trials revealed that the concurrent approach 
of chemoradiotherapy enhanced survival compared to the sequential approach 
[10–13]. After 2000, the usefulness of several new agents, such as paclitaxel, 
gemcitabine, vinorelbine, and docetaxel, which are called third-generation 
chemotherapy agents, have been studied. They have been usually administered in 
combination with platinum compounds, and demonstrated increased survival in 
patients with metastatic NSCLC [14, 15]. Although there has been no significant 
improvement in survival achieved with chemoradiotherapy using third-generation 
regimens, it has become a standard treatment with a favorable toxicity  
profile [16, 17].
Some clinical studies conducted between 1990s and 2000s showed that 
hyperfractionated, accelerated radiotherapy was superior to the conventional 
fractionated radiotherapy with a feasible toxicity [18–21]. However, the benefit of 
hyperfractionated, accelerated radiotherapy is controversial, with high risk of acute 
esophageal toxicity; and has been less accepted in clinical practice [2, 21, 22]. After 
2000, the utility of consolidation chemotherapy following chemoradiotherapy has 
failed to prove a significant survival benefit [23–25]. A dose escalation of radiother-
apy has been investigated because loco-regional tumor control might be associated 
with better survival; and there is a potential dose–response efficacy in the control 
of NSCLC using this approach [5, 26]. However, RTOG 0617 trial failed to prove 
benefits on overall survival (OS) and progression-free survival (PSF) using the 
escalated doses of 74 Gy compared to the standard dose of 60 Gy in an open-label 
randomized phase 3 study [27]. Volume prescriptions such as D95 using updated 
calculation algorithms in recent clinical trials could reveal a slightly escalated dose 
for the target, in comparison with the point prescription that has been used in 
previous studies. However, the standard regimen of definitive radiotherapy has 
been 60 Gy in 30 fractions.
As shown in Figure 1, the median survival time after treatment has improved 
with the development of chemoratiotherapy. However, the 5-year survival rate 
has been unsatisfactorily, reaching only up to 20%. Recently, immune checkpoint 
inhibitors (ICIs) have been applied in the treatment of advanced malignancies, 
including lung cancer [29]. ICIs block checkpoint proteins that can weaken immune 
responses by T cells to cancer cells. Recent systematic reviews have demonstrated 
the beneficial effects of ICIs on OS and PSF in advanced NSCLC [30]. The PACIFIC 
trial, a randomized, double-blind, placebo-controlled multi-center trial, has tested 
the efficacy of dulvalumab, which is a human monoclonal antibody directed against 
programmed cell death-ligand 1 (PD-L1), in patients with stage III NSCLC as 
sequential treatment following standard concurrent chemoradiotherapy [19–32]. 
Dulvalumab has brought a breakthrough in the treatment of locally advanced 
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NSCLC in decades, and median survival after treatment has not reached with a 
median follow-up of 33.3 months in a recent updated result [28]. The transition of 
standard definitive radiotherapy for locally advanced NSCLN and representative of 
the clinical outcomes of selected prospective clinical trials with time are shown in 
Table 1 and Figure 1.
Figure 1. 
Improvement of survival outcome of locally advanced NSCLN. (A) Median survival and (B) 3-year overall 
survival per selected prospective clinical studies and meta-analyses [4–13, 16, 17, 23, 24, 27, 28]. Each bar 
indicates the mean value of the results. Radiotherapy group included locally advanced NSCLC patients who 
underwent treatment with standard radiation doses such as ≥60Gy in a conventional schedule. Abbreviations: 
Con-CRT, concurrent chemoradiotherapy; Con-CRT-ICI, concurrent chemoradiotherapy with consolidation 
immune checkpoint inhibitor; RT, radiotherapy; Seq-CRT, sequential chemoradiotherapy.
~ 1980s Radiotherapy alone
1990s Sequential chemoradiotherapy
Concurrent chemoradiotherapy (second-generation regimen)
2000s Concurrent chemoradiotherapy (third-generation regimen)
2020~ Concurrent chemoradiotherapy followed by immune checkpoint inhibitor (dulvalumab)
Table 1. 
Transition of standard definitive radiotherapy for locally advanced NSCLN.
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3.  Utility of intensity-modulated radiotherapy, learning from RTOG 
0617 and PACIFIC trials
RTOG 0617 trial failed to demonstrate the benefit of dose-escalation of 74 Gy 
compared with 60 Gy, but also provided significant information for clinical practice, 
as it was the first phase III NSCLC study to allow intensity-modulated radiotherapy 
(IMRT) as a treatment modality for locally advanced NSCLC, and 46% of enrolled 
patients underwent IMRT [27, 33].
The disadvantage of IMRT in terms of dose distribution is increased volume 
of lungs receiving low-dose radiation, called “low-dose bath” because the IMRT 
plan is created using the increased number of beam angles [34]. Low-dose baths 
represented by large volumes of lung V5 (the volume of the lungs receiving 
≥5 Gy) has been reported to increase the risk of acute and late pulmonary toxicity 
[34–36]. IMRT was used to treat larger and unfavorable tumors in RTOG 0617 
[37]. Lung V5 was significantly higher in the IMRT group than in the 3D-CRT 
group. However, IMRT was associated with lower rates of severe pneumonitis 
in the RTOG 0617 prospective clinical trial. In addition, severe pneumonitis 
was predicted by lung V20, but not V5. Thus, V20 has been confirmed as a well-
established risk factor of radiation pneumonitis with high reproducibility [38]. It 
is difficult to clarify the controversial meaning of V5 as a predictor of radiation 
pneumonitis. However, IMRT could improve target coverage and reduce the 
volume of normal lungs irradiated with intermediate doses such as V20 [34]. 
Grade ≥ 2 pneumonitis after chemoradiotherapy was a significant exclusion 
criterion in the PACIFIC trial [31]. The reduction of the risk of radiation pneumo-
nitis by using IMRT might maximize the opportunity of receiving consolidation 
ICI based on the PACIFIC trial, although detailed data on radiotherapy was not 
collected in the PACIFIC trial [28, 31, 32, 37].
Higher doses to heart and esophagitis were associated with poor survival 
[37, 39]. In patients receiving heart V50 < 25% versus ≥25, the 1-year OS rates 
were 70.2% versus 46.8% and the 2-year OS rates were 45.9% versus 26.7% 
(p < 0.0001) [39]. Heart V40, which has been shown to be a prognostic factor for 
survival, can be substantially reduced with IMRT compared to 3D-CRT. In addi-
tion, the use of IMRT was associated with significantly less decline in quality of 
life [40]. These toxicities were potentially associated with poor survival in patients 
treated with escalated radiation doses of 74 Gy [27]. Furthermore, the correlation 
of institution accrual volume with the treatment outcomes is controversial but can 
be associated with other malignancies such as head and neck cancers [39, 41–43]. 
Quality assurance and institutional experience seem important in radical treat-
ment of locally advanced NSCLC.
The benefits of proton therapy have been reported and included a better dose 
distribution to the lung and heart in treatment plan than in photon radiotherapy 
[44]. A randomized control study that compared the utility of proton therapy with 
that of IMRT showed no significant benefit in terms of the occurrence of radia-
tion pneumonitis and local failure [45]. Modern proton techniques might improve 
clinical outcomes, but there is no significant evidence of a superiority of proton 
therapy over IMRT at this moment.
IMRT allows the treatment of challenging cases with dosimetric and clinical 
benefits. Therefore, IMRT is a current standard technique in the definitive radio-
therapy for advanced NSCLC, as the use of IMRT has various advantages over 
3D-CRT, which obviously outweighs the disadvantages.
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4. Tips for using definitive radiotherapy for locally advanced NSCLC
4.1 Involved-field radiotherapy
The European Society for Radiotherapy and Oncology recommends that meta-
static nodes and the applicable margin with no further elective lymph nodes should 
be included in clinical tumor volume (CTV) [46]. Radiotherapy has been prescribed 
to the intersection point of the treatment beams [18]. An initial radiotherapy was 
administered to the anteroposterior parallel–opposed pair of portals and then to a pair 
of oblique fields during the boosted radiotherapy [16]. Traditionally, definitive radio-
therapy for locally advanced NSCLC targets the primary disease and nodal metastases 
as well as the mediastinum and ipsilateral hilum whether or not there is clinical 
involvement of all nodal stations [6, 7, 9–11, 13, 17, 18, 22]. This technique is known as 
elective nodal irradiation (ENI). Potential dose–response has been reported, and an 
increased radiation dose has been believed to improve survival in NSCLC before RTOG 
0617 [5, 26]. Involved field radiotherapy (IFRT) is a radiation treatment technique that 
minimizes the radiation dose to uninvolved areas [47]. For example, Figure 2 indicates 
the difference in planning target volume (PTV) between ENI and IFRT. IFRT allows 
radiation doses to be increased to the primary tumor and involves mediastinal lymph 
nodes. Thus, landmark clinical trials testing dose escalation adopted IFRT [27, 48, 49]. 
Although there are limited data directly comparing IFRT and ENI, the elective nodal 
failure rate after IFRT has been reported to be <10% in most reports [50–56]. Generally, 
EFRT can decrease the risk of severe toxicities, including acute esophagitis and pneu-
monitis, while showing no significant differences in elective nodal failure rate and sur-
vival outcomes in comparison with ENI [54–56]. Importantly, metastatic nodes should 
be defined with the guidance of PET images [46, 57]. Thereafter, CTV is generated by 
adding 5 to 10 mm to the gross tumor volume (GTV) of the primary tumor (typically 
8 mm and 6 mm for adenocarcinoma and squamous carcinoma, respectively) and 
3 mm for GTV of metastatic nodes of <20 mm [46, 58, 59].
Figure 2. 
Differences in radiotherapy target selection in elective nodal irradiation and involved field radiotherapy. 
Squamous cell carcinoma in the upper lobe of the right lung with nodal metastases (cT3N2M0). Red, green, 
and blue indicates gross tumor volume (GTV), planning target volume (PTV) for elective nodal irradiation 
(ENI), and that for involved field radiotherapy (IFRT), respectively. The clinical target volume (CTV) for ENI 
including the upper mediastinum enlarges the size of the PTV.
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4.2 Respiratory management in locally advanced NSCLC
An important challenge for lung cancer radiotherapy treatment is the manage-
ment of physiological movements related to breathing. The lung tumors can move 
during breathing. Usually, to ensure adequate dose delivery to the tumor, an appro-
priate margin is added around the tumor. Four-dimensional computed tomography 
(4DCT) is a technique that allows to quantify the movement of the tumor with the 
use of respiratory reduction equipment such as an abdominal compression device. 
The internal target volume (ITV) is delineated on the 4DCT scan in order to account 
for tumor motion, and an additional margin is added to generate PTV. However, the 
target is large as it covers the entire tumor motion, especially in tumors in the lower 
lobe of the lung [60].
The breath-hold technique has been used to minimize the target volume, which 
must be irradiated with high-dose radiation and can help to reduce risk of radiation 
pneumonitis (Figure 3). In particular, the deep inspiration breath hold (DIBH) 
technique provides an advantage to a free-breathing treatment and could reduce the 
dosimetric parameters of normal organs such as the lung in dose-volume histo-
grams [61]. DIBH gating has been clinically used in thoracic and upper abdominal 
radiotherapy [62]. In addition, it has recently been reported that compliance and 
reproducibility of DIBH was sufficiently high, with a reported compliant rate of 
72% in a prospective clinical study [63]. DIBH has a high potential as a standard 
treatment in definitive radiotherapy for locally advanced NSCLC.
4.3 Image-guided radiotherapy in locally advanced NSCLC
In recent years, advancements in image-guided radiotherapy (IGRT) technology 
have enabled more accurate positioning and precise radiotherapy. IGRT is an essential 
companion to IMRT and allows the treatment to account for daily changes in target 
anatomy, motion, and positioning. Megavoltage (MV) portal imaging had been 
conventionally used to correct the setup errors and limited to verification of bony 
anatomy. In recent years, the X-ray source for imaging has been evolving from MV 
imaging to kilovoltage (kV) imaging, and from two-dimensional to three- dimensional 
Figure 3. 
Breath hold technique can minimize a target volume. Non-small cell lung cancer in the lower lobe of the left 
lung. Red, orange blue, and green indicate gross tumor volume (GTV), accumulated GTV on four-dimensional 
computed tomography (4DCT), planning target volume (PTV) using the breath-hold technique (exhale), 
and PTV, which was generated by accounting tumor motion in 4DCT, respectively. The breath-hold technique 
reduces the target volume.
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imaging. Modern IGRT is performed with either gantry mounted MV or kV cone beam 
computed tomography (CBCT) or room-mounted kV systems for tracking during 
treatment. IGRT allows for easier and improved accuracy leading more frequent posi-
tioning changes with leading to a therapeutic advantage. Kilburn et al. has reported 
that IGRT using daily CBCT improved locoregional tumor control than radiotherapy 
using weekly MV portal images [64].
Three-dimensional images in CBCT are used not only for positioning but also 
for the evaluation of the radiotherapy planning by dose calculation on the CBCT 
images. It has recently been reported that dose distribution and dose volume 
histogram were accurately calculated on CBCT images with a deformable imaging 
registration [65].
Further, acquired images from CBCT can be used for individualized treatment, 
called adaptive radiotherapy (ART). Since there are possibe changes of tumor and 
surround tissues during the treatment courses due to tumor shrinking and ana-
tomical changes, it is necessary to modify the radiotherapy plan with accounting  
the appropriate margin, positioning, and tumor. CBCT provides significant 
three-dimensional information to evaluate if the patient would benefit from a 
re-scanning and re-planning. Indeed, ART can improve locoregional tumor control 
over radiotherapy without ART [66].
Daily IGRT with CBCT and ART has been reported to reduce toxicity and 
probably increase tumor response due to a better tumor localization and reduction 
of an interfraction target miss due to anatomical changes [64, 66, 67]. Further 
studies should be conducted in order to establish the optimal systemic replanning 
technique.
5.  Future perspectives of definitive radiotherapy for locally advanced 
NSCLC
5.1 Failure pattern and potential salvage after definitive radiotherapy
Approximately 40% and 50% of locally advanced NSCLC patients experience 
locoregional and distant failures two years after the definitive chemoradiotherapy 
[27]. Consolidation ICI has been proven to reduce disease progression in both the 
intrathoracic and extrathoracic areas [32, 68]. Time to death or distant metastasis 
was longer, and the frequency of new lesions was lower with the use of durvalumab 
in comparison with placebo [32]. Notably, distant failure occurred in one or two 
lesions (66.6% in durvalumab arm) in a single organ (95.2% in durvalumab arm) 
at first progression in both arms of durvalumab and placebo with a median follow-
up of 25.2 months [68]. Therefore, there seems to be a window of opportunity for 
treating these limited failures as a salvage, which might lead to a longer survival 
[69–71]. Cutting-edge radiotherapies, such as stereotactic radiotherapy and particle 
therapy, have the potential to be a prospective option as a salvage modality.
The results of the PACIFIC clinical trial have led to the design of several clinical 
trials combining radiotherapy with ICIs, including PACIFIC-2 study, where a chemo-
radiotherapy plus durvalumab arm is currently studied (NCT03519971). In addition, 
combining chemotherapy, radiotherapy, and ICIs with surgical resection is also 
under investigation in clinical trials (NCT03694236, NCT03237377, NCT04073745, 
NCT03348748).
There are oncological differences between pathological subtypes in NSCLC, as 
widely known in metastatic diseases [72]. Ito et al. showed that adenocarcinoma 
and squamous cell carcinoma tended to develop distant and locoregional fail-
ures, respectively, after chemoradiotherapy for locally advanced NSCLC [73]. In 







NCT04432142 Phase 2 Immune changes after concurrent chemoradiation followed by 
durvalumab
NCT03589547 Phase 2 Durvalumab and consolidation SBRT following chemoradiation
NCT04092283 Phase 3 Durvalumab as concurrent and consolidative therapy or 
consolidative therapy alone




Chemoradiotherapy with ipilimumab followed by nivolumab
NCT04310020 Phase 2 Hypofractionated radiotherapy followed by atezolizumab
NCT03693300 Phase 2 Durvalumab following sequential chemotherapy and radiotherapy
NCT04249362 Phase 2 Durvalumab following radiotherapy (standard or 
hypofractionated bioequivalent dose)
NCT04392505 Phase 2 Investigating biomarkers related to chemoradiation followed by 
durvalumab
NCT04505267 Phase 1 Reirradiation with NBTXR3 for locoregional recurrence
Searched for: radiotherapy, immune | Recruiting, Not yet recruiting Studies | Non-small Cell Lung Cancer Stage III 
at https://clinicaltrials.gov with excluding trials including surgery on Sep. 7, 2020.
Table 2. 
Ongoing phase 1 to 3 clinical trials for locally advanced NSCLN in terms of definitive radiotherapy and 
immune therapy.
addition, non-squamous cell carcinoma tends to benefit more from adding dur-
valumab than squamous cell carcinoma, although there is a lack of direct compari-
son analysis [32]. The effects of histopathological and oncological differences in 
NSCLC on definitive chemoradiotherapy should be investigated with the aim of 
developing a precision treatment for locally advanced NSCLC.
5.2 Immune enhancement and preservation in radiotherapy
Recent developments in immunotherapy have started a new era in the treatment 
of various malignancies, including NSCLC [29, 30, 74]. Induction of the expression 
of immune checkpoint molecules such as PD-L1 results in the inhibition of T cell 
function and immune tolerance of tumors.
Radiation may cause immune activation through cytokine signaling and tumor 
antigen release [75, 76]. However, PD-L1 expression in tumors has been reported 
to be upregulated by radiation exposure in both pre-clinical and clinical set-
tings and can suppress the immunogenic effect on tumors [75–78]. ICIs block the 
immunosuppressive mechanisms of cancer cells and have a synergistic effect in 
combination with radiotherapy [75, 77]. The addition of durvalumab was proven to 
benefit disease control and survival after definitive chemoradiotherapy for locally 
advanced NSCLC [28, 31, 32]. The density of CD8+ tumor-infiltrating lymphocytes 
was significantly associated with favorable survival in locally advanced NSCLC 
patients undergoing chemoradiotherapy [79]. In their report, PD-L1 expression, 
which could be blocked by ICIs, was associated with inferior survival. In addition, 
radiation-induced lymphopenia has been reported to be associated with inferior 
survival [80, 81]. Therefore, radiotherapy will be modified to enhance the immune 
response to tumors. Hypofractionated regimens might have less immunosuppres-
sive effects and are more appropriate than conventional fractionated regimens in 
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terms of immune preservation [82, 83]. A clinical trial has been designed to test 
the addition of durvalumab to two schedules of radiotherapies of conventional and 
hypofractionated schedules (NCT03801902). Ongoing clinical trials in terms of 
definitive radiotherapy combined with ICIs are summarized in Table 2.
PTV size can be associated with circulating blood, including the leukocytes [84]. 
Thus, IFRT is appropriate in terms of not only reducing the risk of pneumonitis 
but also preservation of the host immune system. Ladbury et al. have presented 
a predictive model of the estimated dose of radiation to immune cells, which was 
calculated using the radiation doses for heart, lung, body, and number of fractions, 
and was associated with cancer-specific outcomes [85]. Thereafter, sparing the host 
immune system will be discussed, and new optimizing theory for IMRT should be 
investigated in the future. Radio-immune therapy strategy is giving a new direc-
tion to radiotherapy and is warranted to explore future definitive radiotherapy for 
locally advanced NSCLC.
6. Conclusions
In this chapter, the historical improvement and the current recommendation 
of definitive radiotherapy for locally advanced NSCLC are described. The current 
standard treatment for locally advanced NSCLC is definitive radiotherapy, concur-
rently combined with chemotherapy, followed by anti-PD-L1 treatment. In order 
to improve outcomes and minimize radiation-induced toxicity, IMRT using an 
involved-field under modern management of respiration is a present recommenda-
tion in this chapter. An optimal combination of radiotherapy and immunotherapy 
should be warranted in a future investigation.
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